A Randomized, Open-Label, Multi-center, Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) Monotherapy or HLX43 in Combination with HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody Injection) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2026
This article has no abstract
Epistemonikos ID: b24e645481f582be9747fbcb3bc8f9254a90558b
First added on: Jul 25, 2026